Kamada (KMDA) said Wednesday it was awarded a contract with an unnamed international organization to supply Kamrab and Varizig in Latin America for the 2025-2027 period.

Revenue under the three-year contract is expected to be about $25 million, the company said.

Kamrab is indicated for the prevention of rabies infection after contact with rabid or possibly rabid animals, while Varizig is a varicella drug for post-exposure prophylaxis in high-risk individuals, Kamada said.

The company's shares were rising past 5% in recent trading.

Price: 7.48, Change: +0.40, Percent Change: +5.64